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In people suffering from schizophrenia, major areas of everyday life are impaired, including independent living, productive activities and
social relationships. Enhanced understanding of factors that hinder real-life functioning is vital for treatments to translate into more positive
outcomes. The goal of the present study was to identify predictors of real-life functioning in people with schizophrenia, and to assess their
relative contribution. Based on previous literature and clinical experience, several factors were selected and grouped into three categories:
illness-related variables, personal resources and context-related factors. Some of these variables were never investigated before in relationship
with real-life functioning. In 921 patients with schizophrenia living in the community, we found that variables relevant to the disease, per-
sonal resources and social context explain 53.8% of real-life functioning variance in a structural equation model. Neurocognition exhibited
the strongest, though indirect, association with real-life functioning. Positive symptoms and disorganization, as well as avolition, proved to
have significant direct and indirect effects, while depression had no significant association and poor emotional expression was only indirectly
and weakly related to real-life functioning. Availability of a disability pension and access to social and family incentives also showed a sig-
nificant direct association with functioning. Social cognition, functional capacity, resilience, internalized stigma and engagement with men-
tal health services served as mediators. The observed complex associations among investigated predictors, mediators and real-life functioning
strongly suggest that integrated and personalized programs should be provided as standard treatment to people with schizophrenia.
Key words: Schizophrenia, real-life functioning, neurocognition, positive symptoms, disorganization, avolition, personal resources, resilience,
internalized stigma, engagement with mental health services
(World Psychiatry 2014;13:275-287)
Despite significant advances in pharmacological and psy-
chological treatments, schizophrenia still ranks among the first
ten leading causes of disability worldwide. It has a direct nega-
tive influence on the real life of about 26 millions of people
and an indirect negative impact on more than twice this num-
ber when considering patients’ relatives and caregivers (1).
Major areas of everyday life are impaired, including indepen-
dent living, productive activities and social relationships (2).
The lessening of symptoms and the reduction of relapse
rate contributes to improve real-life functioning, but is not suf-
ficient to attain functional recovery (3-6). Enhanced under-
standing of factors that hinder functioning in schizophrenia is
vital for treatments to translate into more positive outcomes
(7). Studies carried out so far have led to partial and some-
times discrepant findings. Furthermore, they usually focused
on neurocognitive deficits, negative symptoms and depres-
sion, and often failed to simultaneously consider several rele-
vant variables (8-10).
For neurocognitive impairment, small to large correla-
tions with global indices of functioning have been reported,
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depending on the investigated domains, the use of a com-
posite score (higher correlations for the composite score than
for individual cognitive domains) and the rater of patient
functioning (higher correlations for clinician rating than for
patient self-report) (11,12). Recent studies have shown that
the impact of neurocognitive impairment may be mediated
by functional capacity, i.e., the ability to perform tasks rele-
vant to everyday life in a structured environment, guided by
an examiner. In some studies, the impact of cognitive impair-
ment on real-life functioning was negligible when functional
capacity was included in the model (13,14). Discrepant
results have also been reported, i.e., no correlation between
neurocognitive indices or functional capacity and self-
reported real-life functioning (15), or a significant influence
of neurocognitive dysfunction on everyday-life functioning
in the presence of no influence of functional capacity (16).
Social cognition is currently considered a domain partly
independent of neurocognitive functions and encompassing a
large array of mental functions, from social perception to
affect recognition, to theory of mind (17,18). Relationships
between deficits in social cognition and impaired social and
occupational functioning have been reported (17,19,20). Ac-
cording to some studies, social cognition mediates the effect of
neurocognitive impairment on real-life functioning (21,22).
Negative symptoms have also been associated with pa-
tients’ functional outcome (9,23,24). Both direct and indirect
relationships between this psychopathological domain and
real-life functioning have been reported (7,13). Evidence of
the role of negative symptoms as mediators of the impact of
other variables (i.e., neurocognition or functional capacity) on
real-life functioning has also been provided (9,25). However,
several limitations of previous studies might prevent solid
conclusions and generalizability. In fact, negative symptoms
have generally been regarded as a unitary construct, while
the most recent literature suggests that these symptoms are
heterogeneous and include at least two factors, “avolition”
and “poor emotional expression”, that might be underpinned
by different pathophysiological substrates (26,27) and show
different relationships to functional outcome (23). Moreover,
largely used scales for the assessment of negative symptoms
have been criticized for the inclusion of items assessing neuro-
cognition and the focus on behavioral aspects, as opposed to
internal experience, which may lead to artefactual associa-
tions with functional outcome measures (28,29).
An impact of depressive symptoms on real-life function-
ing in schizophrenia has also been reported (30-32). How-
ever, an association has generally been found only when
studies examined subjective indicators of real-life function-
ing (13,33), suggesting that depression affects person’s self-
evaluation of functioning but not “real” functioning. The
symptoms of depression may also affect functioning by
interfering with subject’s motivation and ability to properly
organize him/herself in daily living activities. In this respect,
the simultaneous evaluation of negative and depressive symp-
toms is important to clarify the relative contribution of these
two psychopathological domains to real-life functioning.
Besides the variables summarized above, some studies
have reported that patients with comparable severity of psy-
chopathology may differ in their real-life functioning as a
result of differences in personal resources (34-36). Resilience
is a construct encompassing several aspects of personal re-
sources. It is variously defined as a personal trait protective
against mental disorders and a dynamic process of adapta-
tion to challenging life conditions (37-40). In patients with
schizophrenia, a significant correlation between resilience
and psychosocial functioning has been reported (41); further-
more, lower baseline resilience was found among ultra-high
risk subjects who converted to frank psychosis than among
those who did not (42). Resilience is also related to patterns
of mental health service engagement of patients with schizo-
phrenia, which can affect real-life functioning (43).
Although it is obvious that real-life functioning is also influ-
enced by the societal context, which includes disability com-
pensation, job or housing opportunities, residential support,
and various elements of attitudes and stigma (2), the identifi-
cation of the most appropriate indices to capture the com-
plexity of these variables is not an easy task. The evaluation of
subjects’ functioning with respect to employment or housing,
for example, must take into account the offer of employment
or housing in the place where the patient lives and the avail-
ability of social support, such as a disability pension. Accord-
ing to a recent study, differences in residential outcomes are
likely based on differences in social services systems (44).
Similarly, in a two-year follow-up of people with schizophre-
nia after their first episode, only those who were receiving dis-
ability compensation or were supported by their families were
living independently (45). Indeed, it appears likely that inter-
ventions which modify the level of social support have an
impact on real-life functioning in people with schizophrenia.
A higher level of internalized stigma – the process where-
by people with severe mental disorders anticipate social
rejection and consider themselves as devalued members
of society (46-48) – has been found in association with lower
levels of hope, empowerment, self-esteem, self-efficacy, qual-
ity of life, social support and adherence to treatment (49),
suggesting an impact of this variable on real-life functioning,
and the need to consider it in relevant studies.
From the summarized evidence, it is clear that real-life
functioning of people with schizophrenia depends on a num-
ber of variables, some related to the disease, others to personal
resources, and some more to the context in which the person
lives. In the light of this complexity, it is crucial to consider all
these aspects in order to explore their relative contribution.
In this paper we report on a large Italian multicenter
study aimed to identify factors affecting real-life functioning
of patients with schizophrenia and to assess their relative
contribution. Factors to be included were chosen in the light
of the literature review briefly summarized and of clinical
experience, and were grouped into three categories: illness-
related variables, personal resources and context-related
variables. We predicted a significant association between
the impairment of real-life functioning and the severity of
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negative symptoms and cognitive deficits, such as the more
severe the negative symptoms and cognitive deficits, the
more impaired the everyday functioning. As to negative
symptoms, we expected that avolition would show a stron-
ger association with real-life functioning than poor emo-
tional expression. An association between neurocognition
and real-life functioning was also expected, partly or entirely
mediated by functional capacity and social cognition. We
also hypothesized that the variables included among per-
sonal resources mediate the impact of symptoms and cogni-
tive impairment on real-life functioning. Due to the paucity
of literature data, it was more difficult to predict which
context-related variables would show a direct or indirect
association with real-life functioning. Nevertheless, we antic-
ipated that a large social network and having access to social
and family incentives would have a favorable impact on func-
tioning, and that internalized stigma would mediate the influ-
ence of symptoms and cognitive deficits on functioning.
Several limitations of previous studies were addressed
in the present investigation. The Brief Negative Symptom
Scale (BNSS, 28) was used to assess negative symptoms;
this is a recently developed instrument designed to over-
come the above-mentioned limitations of other largely used
scales for the assessment of negative symptoms. Depressive
and extrapyramidal symptoms were evaluated to ascertain
their possible influence on negative symptoms and real-life
functioning. The MATRICS (Measurement and Treatment
Research to Improve Cognition in Schizophrenia) Con-
sensus Cognitive Battery (MCCB) was chosen for cognitive
assessment, as it is regarded as the “state of the art” neuro-
psychological battery for research purposes in schizophre-
nia (50,51). A full assessment of different aspects of social
cognition was carried out, including emotional intelligence,
emotion recognition and theory of mind. Personal resources
and context related factors were included in the study.
In the light of difficulties in defining and measuring real-
life functioning (2), the Specific Levels of Functioning Scale
(SLOF) was selected to measure social, vocational, and ev-
eryday living outcomes (52). This instrument was endorsed
by the panel of experts involved in the Validation of Every-
day Real-World Outcomes (VALERO) initiative as a suit-
able measure of real-life functioning (12,53).
Due to the high number of included variables, a large mul-
ticenter study was designed to be carried out in 26 university
psychiatric clinics and/or mental health departments,
recruiting up to 1000 subjects with schizophrenia.
METHODS
Participants
Study participants were recruited from patients living in
the community and consecutively seen at the outpatient
units of 26 Italian university psychiatric clinics and/or men-
tal health departments. Inclusion criteria were a diagnosis
of schizophrenia according to DSM-IV, confirmed with the
Structured Clinical Interview for DSM-IV - Patient version
(SCID-I-P), and an age between 18 and 66 years. Exclusion
criteria were: a history of head trauma with loss of con-
sciousness; a history of moderate to severe mental retarda-
tion or of neurological diseases; a history of alcohol and/or
substance abuse in the last six months; current pregnancy or
lactation; inability to provide an informed consent; treat-
ment modifications and/or hospitalization due to symptom
exacerbation in the last three months.
All patients signed a written informed consent to partic-
ipate after receiving a comprehensive explanation of the
study procedures and goals.
Procedures
Approval of the study protocol was obtained from the
Local Ethics Committees of the participating centers. Recruit-
ment took place from March 2012 to September 2013.
Enrolled patients completed the assessments in three days
with the following schedule: collection of socio-demographic
information, psychopathological evaluation and neurological
assessment on day 1, in the morning; assessment of neurocog-
nitive functions, social cognition and functional capacity on
day 2, in the morning; assessment of personal resources and
perceived stigma either on day 3 (morning or afternoon) or in
the afternoon of day 1 or 2, according to the patient’s prefer-
ence. For real-life functioning assessment, patient’s key care-
giver was invited to join one of the scheduled sessions.
Assessment tools
Evaluation of illness-related factors
A clinical form was filled in with data on age of disease
onset, course of the disease and treatments, using all avail-
able sources of information (patient, family, medical records
and mental health workers).
The Positive and Negative Syndrome Scale (PANSS, 54)
was used to rate symptom severity. Scores for the dimen-
sions “disorganization” and “positive symptoms” were cal-
culated based on the consensus 5-factor solution proposed
by Wallwork et al (55).
Negative symptoms were assessed using the BNSS,
which includes 13 items, rated from 0 (normal) to 6 (most
impaired), and five negative symptoms domains: anhedo-
nia, asociality, avolition, blunted affect and alogia. The Ital-
ian version of the scale was validated as part of the Italian
Network for Research on Psychoses activities. In line with
previous research (28,56), domains evaluated by the scale
loaded on two factors: “avolition”, consisting of anhedonia,
asociality and avolition, and “poor emotional expression”,
including blunted affect and alogia.
Depressive symptoms were evaluated using the Calgary
Depression Scale for Schizophrenia (CDSS, 57), a rating
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scale designed to assess the level of depression in people
with schizophrenia.
Extrapyramidal symptoms were assessed by means of the
St. Hans Rating Scale (SHRS, 58), a multidimensional rating
scale consisting of four subscales: hyperkinesias, parkinson-
ism, akathisia and dystonia. Each subscale includes one or
more items, with a score ranging from 0 (absent) to 6 (severe).
Neurocognitive functions were rated using the MCCB.
This battery includes tests for the assessment of seven dis-
tinct cognitive domains: processing speed, attention/vigi-
lance, working memory, verbal learning, visual learning,
social cognition, and reasoning and problem solving.
The assessment of social cognition, partly included in the
MCCB Mayer-Salovey-Caruso Emotional Intelligence Test
(MSCEIT) managing emotion section, was integrated by the
Facial Emotion Identification Test (FEIT, 59) and The
Awareness of Social Inference Test (TASIT, 60), which is a
theory of mind test.
Assessment of personal resources
Resilience was evaluated by the Resilience Scale for Adults
(RSA, 61), a self-administered scale including 33 items that
examine intra- and inter-personal protective factors thought
to facilitate adaptation when facing psychosocial adversity.
Items are organized in six factors: perception of self, percep-
tion of the future, structured style, social competence, family
cohesion, and social resources. To avoid overlap with other
measures, the “structured style” and “social resources” factors
were not included in the analysis.
The Service Engagement Scale (SES, 62), an instrument
including 14 items, rated on a 4-point Likert scale (with
higher scores reflecting greater levels of difficulty engaging
with services), was used to explore patients’ relationship
with mental health services. Items are grouped into four sub-
scales: availability, cooperation, help seeking, and adherence
to treatment. In the present paper, we used the total score pro-
vided by the instrument.
Evaluation of context-related factors
A socio-demographic questionnaire was developed ad
hoc to collect data on gender, age, marital status, schooling,
housing, eating habits, substance use, socio-economic sta-
tus, availability of a disability pension, and access to family
and social incentives.
The socio-economic status was determined from the edu-
cation level and the type of work of each parent. The educa-
tion level was measured on a 7-level scale (15elementary
school, 75post-degree/specialization courses) and the type
of work was ranked on 9 levels (15laborer, 95high level
managerial position). The Hollingshead index was calculat-
ed as the average of the indices of the two parents (63).
The Social Network Questionnaire (SNQ, 64) was used
to assess structural and qualitative aspects of participants’
social network. This is a self-administered questionnaire
including 15 items rated on a 4-point scale (from 1 "never"
to 4 "always"), organized into four factors: quality and fre-
quency of social contacts, practical social support, emotion-
al support, and quality of an intimate relationship.
The Internalized Stigma of Mental Illness (ISMI, 65) was
used to evaluate the experience of stigma and internalized
self-rejection. It includes 29 items and 5 subscales for self-
assessment of subjective experience of stigma. Each item is
rated on a 4-level Likert scale, where higher scores indicate
greater levels of internalized stigma.
Assessment of functional capacity and real-life functioning
Functional capacity was evaluated using the short ver-
sion of the University of California San Diego (UCSD)
Performance-based Skills Assessment Brief (UPSA-B, 66), a
performance-based instrument that assesses “financial skills”
(e.g., counting money and paying bills) and “communication
skills” (e.g., to dial a telephone number for emergency or
reschedule an appointment by telephone). The total score,
ranging from 0 to 100, was used in statistical analyses.
Real-life functioning was assessed by the Specific Level
of Functioning Scale (SLOF), a hybrid instrument that
explores many aspects of functioning and is based on the
key caregiver’s judgment on behavior and functioning of
patients. It consists of 43 items and includes the following
domains: physical efficiency, skills in self-care, interperson-
al relationships, social acceptability, community activities
(e.g., shopping, using public transportation), and working
abilities. Higher scores correspond to better functioning. In
our study, the key relative was interviewed, as usually this is
the individual most frequently and closely in contact with
the patient in the Italian context. The Italian version of the
scale has recently been validated (67).
Training of researchers
For each category of variables (illness-related factors, per-
sonal resources and context-related factors), at least one
researcher per site was trained. In order to avoid halo effects,
the same researcher could not be trained for more than one
category.
The inter-rater reliability was formally evaluated by Co-
hen’s kappa for categorical variables, and intraclass correla-
tion coefficient (ICC) or percentage agreement for continuous
variables. An excellent inter-rater agreement was found for
the SCID-I-P (Cohen’s kappa50.98). Good to excellent
agreement among raters was observed for SLOF (ICC50.55-
0.99, percentage agreement570.1-100%); BNSS (ICC50.81-
0.98); PANSS (ICC50.61-0.96, percentage agreement567.7-
93.5%); CDSS (ICC50.63-0.90) and MCCB (ICC50.87).
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Statistical analysis
The demographic and clinical characteristics of study
participants and the scale scores were summarized as mean
6SD, median and interquartile range, and percentages
where appropriate.
Structural equation models (SEM) were used to test
the relationships of variables inherent to illness, personal
resources and context with real-life functioning. These mod-
els can be interpreted as a set of simultaneous multiple re-
gression models, in which variables can serve as predictors
or outcomes. As a preliminary step, we examined the pair-
wise correlation and covariance matrix for the study varia-
bles. Given the large number of cases, correlations were
interpreted taking into account the absolute value of the
correlation coefficient and not its significance. We chose to
consider correlation coefficients between predictors and
SLOF scales0.20 as trustworthy.
Since two variables may be connected in a SEM through
several pathways, direct effects, indirect effects and total ef-
fects were estimated. A direct effect is a relationship be-
tween two variables not mediated by any other variable in
the model. An indirect effect of one variable on another is a
relationship mediated by one or more variables along a spe-
cific pathway and is calculated as the product of all the
involved direct effects. The total effect is the sum of the
direct and all indirect effects.
The model parameters, which provide information about
the relationships among the variables, can be interpreted
as standardized regression weights, as in linear regression
models. Squared multiple correlations (R2) were obtained
for each endogenous variable to estimate the amount of var-
iance explained by its predictors. Lastly, the standardized
coefficients for indirect effects were examined to evaluate
mediation effects. Significant effects suggest mediation is
present, and full mediation is indicated by the direct path no
longer being significant.
An advantage of SEM is the use of latent variables. This
implies using more than one variable to map onto a theoreti-
cal construct, thus allowing reduction of the measurement
error and a more accurate estimation of the true value of the
construct than it would be possible using a single variable.
In the present study, neurocognition, social cognition,
resilience and real-life functioning (SLOF) were defined
as latent variables. Neurocognition included the MCCB do-
mains “processing speed”, “attention”, “working memory”,
“verbal memory”, “visual memory” and “problem solving”;
social cognition corresponded to FEIT, TASIT and MSCEIT
scores; resilience combined “perception of self”, “perception
of the future”, “social competence” and “family cohesion”,
and SLOF reflected the five domains of the scale, i.e., “skills
in self-care”, “interpersonal relationships”, “social accept-
ability”, “community activities” and “working abilities”.
For the purpose of the SEM, neurocognition, social cog-
nition and functional capacity variables were standardized
with respect to Italian normative data. All the other varia-
bles were transformed into z-scores. Disability pension was
coded as a dichotomous variable (yes/no). Other incentives,
including financial and/or practical support from the family,
as well as registration in an unemployment list, were used as
a count variable, ranging from 0 to 3.
To define our initial SEM model, we hypothesized rela-
tionships between variables consistent with published re-
search. Specifically, we hypothesized that psychopathology
(including positive symptoms, disorganization, negative symp-
toms and depression), neurocognition, extrapyramidal symp-
toms, incentives, and socio-economic status would predict
functioning both directly and indirectly, through the media-
tion of social cognition and functional capacity. Moreover, we
assumed first that SES, resilience, and ISMI would be further
mediators of the relationship of predictors with functioning
and tested this hypothesis in the model.
The final model was obtained by removing non-significant
effects and correlations among predictors lower than 0.20
and testing alternative hypotheses on the relationships among
mediators.
Model fit was evaluated using the comparative fit index
(CFI, 68), Tucker-Lewis index (TLI, 69) and the root mean
square error of approximation (RMSEA, 70). TLI and CFI
values >0.90 reflect acceptable fit and values >0.95 imply
very good fit (71). RMSEA values<0.05 indicate close mod-
el fit; values up to 0.08 suggest a reasonable error of approxi-
mation in the population, and values>0.10 indicate poor fit
(72). The fit indices were assessed collectively, such that a
single index that fell just outside the acceptable range was
not necessarily considered to reflect poor model fit, provid-
ed that the other statistics indicated good model fit. Power
analysis was carried out using MacCallum et al’s (73) criteri-
on to test the hypothesis of RMSEA’s not-close fit. The best-
fitting models were compared using the Akaike Information
Criterion (AIC, 74). This index has no predefined cut-offs
and can only be interpreted when comparing two different
models. A lower AIC indicates better model fit.
Analyses were carried out using Stata, version 13.1, and
Mplus, version 7.1.
RESULTS
Out of 1691 screened patients, 1180 were eligible; of
these, 202 refused to participate, 57 dropped out before com-
pleting the procedures and 921 were included in the analyses
(641 males, 280 females). Data on demographic and illness-
related variables are provided in Tables 1 and 2. Almost all
patients were treated with antipsychotics, mostly second-
generation drugs, and about one quarter received an inte-
grated treatment, i.e., psychosocial interventions in addition
to pharmacotherapy (including cognitive rehabilitation, psy-
choeducation, social skills training, self-help groups or shel-
tered employment).
Data on personal resources, context-related factors and
functional capacity, and SLOF scale scores are provided in
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Table 3. Overall, study participants showed a modest degree
of functional impairment. SLOF domains showing a moder-
ate degree of impairment included interpersonal relation-
ships, community activities and working abilities.
Inspection of the bivariate correlation matrix revealed
that the socio-economic status (Hollingshead index), the
social network and extrapyramidal symptoms were unre-
lated to all mediators and SLOF; therefore, these variables
were not used in further analyses.
In our first SEM model (Figure 1), PANSS positive, PANSS
disorganization, BNSS avolition, BNSS poor emotional ex-
pression, depression, neurocognition, and incentives were used
as independent predictors; social cognition, functional capaci-
ty, internalized stigma, resilience and service engagement were
used as mediators, and SLOF was the dependent variable.
PANSS positive and PANSS disorganization, as well as
BNSS avolition, proved to have significant direct and indi-
rect effects; depression had no significant effect on SLOF,
and BNSS poor emotional expression was only indirectly
and weakly related with SLOF (Table 4, Figure 1). Neurocog-
nition had only indirect effects on SLOF. Incentives proved
to be a significant predictor, and social cognition, functional
capacity, resilience, internalized stigma and service engage-
ment served as mediators, as hypothesized.
CFI and TLI indices for this model were 0.925 and 0.916,
respectively, and the RMSEA index was 0.047, denoting a
good fit to the data. The included variables explained 53.5%
of SLOF variance.
After trimming non-significant paths (from neurocogni-
tion, CDSS, BNSS poor emotional expression to SLOF, and
from social cognition to internalized stigma), a final model
was obtained with five predictors and five mediators (Figure
2). This model accounted for 53.8% of variance of the
SLOF, was more parsimonious and proved to have a better
fit compared with the initial model (CFI50.940, TLI50.932,
RMSEA50.044). Comparison of the AIC indices for the ini-
tial and the final model (84686.906 and 80400.015, respec-
tively) further supported the choice of the latter to represent
the relationships among variables without loss of information.
In this final model, PANSS positive, PANSS disorganiza-
tion and BNSS avolition showed a negative direct effect on
SLOF (Table 4), indicating that higher levels of psychopa-
thology are associated with poorer functioning. Several
indirect effects on SLOF were also observed: PANSS posi-
tive through service engagement, PANSS disorganization
through functional capacity, and BNSS avolition through
service engagement and resilience. BNSS avolition had also
an effect on internalized stigma that, in its turn, was indi-
rectly associated with SLOF through resilience. Neurocog-
nition showed indirect effects on SLOF through four differ-
ent mediators: service engagement, functional capacity,
internalized stigma (through resilience) and social cogni-
tion, and when compared with other predictors of the same
mediator, it always showed the strongest effect (Figure 2).
Table 4 provides a summary of direct, indirect and total
effects on SLOF of variables included in the final model.
Neurocognition showed the strongest total effect, followed
Table 1 Characteristics of the study sample (N5921)
Gender (% males) 69.6
Age (years, mean6SD) 40.2610.7
Married (% yes) 7.8
Working (% yes) 29.2
Education (years, mean6SD) 11.663.4
Age at first psychotic episode (years, mean6SD) 24.067.2
Antipsychotic treatment (%)
First generation 14.2
Second generation 48.5
Both 14.1
None 3.2
Integrated treatment (% yes) 26.8
Suicide attempts (% yes) 17.1
Table 2 Data on illness-related variables
Mean6SD Min/Max
PANSS positive 9.864.7 4/28
PANSS disorganization 8.663.8 3/21
BNSS poor emotional expressivity 12.868.0 0/33
BNSS avolition 20.769.6 0/45
CDSS (total score) 4.064.0 0/21
TMT (total time) 66.3646.2 15/300
BACS SC (correct responses) 31.5613.2 0/96
Fluency (number animal names) 16.565.7 0/47
CPT-IP (D Prime average) 1.760.8 20.39/4.03
WMS-III SS (correct sequences) 12.364.1 1/26
LNS (correct responses) 10.464.2 0/21
HVLT-R (correct recalls) 19.065.6 0/35
BVMT-R (total score) 16.368.8 0/36
NAB mazes (total score) 9.766.4 0/26
TASIT Sect. 1 (correct items) 19.765.4 0/28
TASIT Sect. 2 (correct items) 36.9611.7 0/60
TASIT Sect. 3 (correct items) 37.4612.2 0/64
FEIT (correct responses) 36.868.5 7/53
MSCEIT (SS-B4) 78.569.0 54.6/109.2
PANSS – Positive and Negative Syndrome Scale, BNSS – Brief Negative Symptom
Scale, CDSS – Calgary Depression Scale for Schizophrenia, TMT – Trail Making
Test - Part A, BACS SC – Brief Assessment of Cognition in Schizophrenia Symbol
Coding, Fluency – Category Fluency, Animal Naming, CPT-IP – Continuous Per-
formance Test, Identical Pairs, WMS-III SS – Wechsler Memory Scale Spatial
Span, LNS – Letter-Number Span, HVLT-R – Hopkins Verbal Learning Test -
Revised, BVMT-R – Brief Visuospatial Memory Test - Revised, NAB – Neuropsy-
chological Assessment Battery, TASIT – The Awareness of Social Inference Test,
FEIT – Facial Emotion Identification Test, MSCEIT – Mayer-Salovey-Caruso
Emotional Intelligence Test, SS-B4 – standard score for the managing emotions
branch
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by disorganization, avolition, functional capacity, service
engagement, social cognition, positive symptoms, incen-
tives, resilience and internalized stigma.
DISCUSSION
To our knowledge, this is the largest study carried out so
far on factors associated with real-life functioning in people
with schizophrenia, in terms of both sample size and num-
ber of investigated domains. According to our findings, vari-
ables relevant to the disease, personal resources and social
context explain 53.8% of real-life functioning variance in pa-
tients with schizophrenia living in the community and treated
with antipsychotics, mainly second-generation drugs.
Neurocognition exhibited the strongest association with
real-life functioning. This result corroborates previous find-
ings of moderate to large correlations of neurocognition
with everyday functioning measures (75-77). Our use of
neurocognition as a latent variable, to reduce its measure-
ment error, further supports the robustness of the finding. In
line with previous research (77,78), neurocognition proved
to be a distal variable with respect to real-life functioning,
since its relationship with SLOF was mediated by functional
capacity, social cognition, service engagement and internal-
ized stigma.
Associations between functional capacity and neurocog-
nition have previously been reported in cross-sectional stud-
ies (79-81). In our model neurocognition was the strongest
predictor of functional capacity, which reflects its important
contribution to the latter construct. Actually, both measures
assess the individuals’ capability of performing tasks and/or
behaviors in a standardized setting, but tests of functional
capacity do so in more “ecological” way, i.e., simulating
everyday life tasks, though not carried out in the community
(15,82). The role of functional capacity as mediator of the
impact of neurocognition on real-life functioning reported in
our study has also been previously observed (13,14).
The correlation between social cognition and real-life
functioning ranged from small to large in previous studies,
mainly depending on the examined aspect of social cogni-
tion, with largest effects observed for theory of mind tasks
(17,20). Our findings confirm that social cognition accounts
for a unique proportion of functioning variance, indepen-
dent of neurocognition (83-87), support its independence
from negative symptoms (18,22), and do not support its role
as mediator of the impact of negative symptoms on real-life
functioning (7).
To our knowledge, the role of service engagement and
internalized stigma as mediators between neurocognition
and real-life functioning has not been investigated in previous
studies. In our model, service engagement was directly asso-
ciated with SLOF, while internalized stigma showed, in its
turn, an indirect association with SLOF, mediated by resil-
ience. Service engagement, as assessed in the present study,
reflects subject’s degree of collaboration with mental health
services (e.g., active participation in defining treatment plans,
ability to seek service help if needed and to show up on time
for the appointments) and adherence to prescribed treat-
ments. According to our results, impaired cognitive function-
ing interferes with subject’s collaboration to treatment and
therefore it is an obstacle to successful outcome.
Internalized stigma, according to a recent meta-analysis
including 127 studies, is directly associated with severity of
psychiatric symptoms and inversely related to levels of hope,
empowerment, self-efficacy, quality of life and adherence to
treatment (49). Our data confirm the previously reported
association between internalized stigma and negative symp-
toms (88), and extend this finding to neurocognition. An
association between social cognition and internalized stigma
has been reported by other authors (89), but has not been
observed in our model. A possible interpretation of this dis-
crepancy could be that the relationship between social cog-
nition and internalized stigma is spurious; in other words, it
Table 3 Data on personal resources, context-related variables
and functioning
Personal resources
SES (total score, mean6SD, min/max) 12.967.7, 0/42
Resilience Scale for Adults (mean6SD, min/max)
Perception of self 18.165.5, 0/30
Perception of future 10.864.3, 0/20
Social competence 18.965.3, 6/30
Family cohesion 20.365.7, 3/30
Context-related factors
ISMI (total score, without stigma
resistance, mean6SD, min/max)
2.160.5, 1.00/3.92
Number of incentives (%)*
None 12.7
One 29.2
Two 32.9
Three 18.2
Four 7.0
Functional capacity and real-life functioning
UPSA-B (total score, mean6SD, min/max) 67.5622.3, 0/100
SLOF (mean6SD, min/max)
Physical functioning 24.261.3, 15/25
Skills in self-care 31.764.0, 10/35
Interpersonal relationships 22.366.1, 7/35
Social acceptability 32.563.3, 14/35
Community activities 45.968.6, 11/55
Working abilities 20.066.2, 6/30
SES – Services Engagement Scale, ISMI – Internalized Stigma of Mental Ill-
ness, UPSA-B – UCSD Performance-Based Skills Assessment, SLOF – Specific
Levels of Functioning
*Including financial support from the family, practical support from the family,
registered in an unemployment list, disability pension
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is possible that neurocognitive impairment underlies both
these variables and therefore accounts for their relationship.
The illness-related variables disorganization, positive
symptoms and avolition were both directly and indirectly
related to functioning. The key role of disorganization
observed in our study deserves comments. The PANSS
items “conceptual disorganization”, “difficulties in abstract
thinking” and “poor attention” are generally considered
Figure 1 Initial structural equation model. Neurocognition, social cognition, resilience and SLOF are latent variables (with arrows pointing to
their respective indicators). PANSS POS, PANSS DISORG, BNSS avolition, BNSS-EE, depression, neurocognition and incentives are inde-
pendent predictors. Social cognition, functional capacity, internalized stigma, resilience and service engagement are mediators, and SLOF is
the dependent variable. PANSS – Positive and Negative Syndrome Scale, POS – positive, DISORG – disorganization, BNSS – Brief Negative
Symptom Scale, EE – poor emotional expression, AVOL – avolition, PROC SPEED – processing speed, ATTN – attention, WORK MEM –
working memory, VERB MEM – verbal memory, VIS MEM – visuospatial memory, PROBL SOLV – problem solving, TASIT – The Awareness
of Social Inference Test, MSCEIT – Mayer-Salovey-Caruso Emotional Intelligence Test, PERC. SELF – perception of self, PERC. FUTURE –
perception of the future, SOCIAL COMPET. – social competence, SLOF – Specific Level of Functioning, PERS – skills in self-care, ACTIV –
community activities, ACC – social acceptability, INTER – interpersonal relationships, WORK – working abilities
Table 4 Direct, indirect and total effects on SLOF in the final model
Direct p Total indirect p Total p
Functional capacity 0.245 <0.001 - - 0.245 <0.001
Social cognition 0.169 <0.001 - - 0.169 <0.001
Internalized stigma - - 20.061 0.001 20.061 <0.001
Resilience 0.116 0.001 - - 0.116 <0.001
Neurocognition - - 0.302 <0.001 0.302 <0.001
PANSS positive 20.117 0.001 20.031 <0.001 20.148 <0.001
PANSS disorganization 20.201 <0.001 20.063 <0.001 20.264 <0.001
BNSS avolition 20.210 <0.001 20.046 0.001 20.255 <0.001
Incentives 20.142 <0.001 - - 20.142 <0.001
Service engagement 20.184 <0.001 - - 20.184 <0.001
SLOF – Specific Levels of Functioning, PANSS – Positive and Negative Syndrome Scale, BNSS – Brief Negative Symptom Scale
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core aspects of the disorganization factor (90-92); in the
present study, the structure of the PANSS disorganization
dimension was defined according to the consensus 5-factor
solution proposed by Wallwork et al (55), in which the three
above-mentioned items load on the disorganization factor.
The overlap of the items “difficulties in abstract thinking”
and “poor attention” with neurocognitive impairment can-
not be underestimated. As a matter of fact, in our data, neuro-
cognition and disorganization showed a significant inverse
correlation and a similar pattern of association with SLOF,
through functional capacity and social cognition.
Avolition had both a direct and an indirect relationship
with SLOF. In the indirect path, it has service engagement,
resilience and internalized stigma (in its turn associated with
SLOF through resilience) as mediators. In the initial model,
both BNSS factors had been included, but BNSS poor emo-
tional expression only showed an indirect and weak relation
with SLOF, and its exclusion from the final model did not
worsen the fit or reduce the explanatory power of the model.
A significant relationship between avolition and poor
social outcome has been reported in previous studies (93-95).
In a recent investigation on long-term stability and outcome
of negative symptoms, Galderisi et al (23) found that avolition
has a higher predictive value of functional outcome than
poor emotional expression at 5-year follow-up. The scarce
relevance of poor emotional expression to real-life function-
ing is in line with Foussias et al’s findings (96).
The strong impact of avolition on real-life functioning
might be due to the partial overlap between these two meas-
ures. However, the degree of overlap was most probably lim-
ited in our study, since avolition, as measured by the BNSS,
provides an assessment of both behavioral (e.g., deficit in initi-
ating and persisting in different activities) and inner experi-
ence aspects (e.g., lack of interest and motivation in different
activities, impaired anticipation of rewarding outcome),
while the real-life assessment provided by a caregiver mainly
focuses on subject’s performance and behavior in several
types of everyday activities. Efforts aimed to improve our
Figure 2 Final structural equation model after trimming of non-significant paths. Neurocognition, social cognition, resilience and SLOF are
latent variables (with arrows pointing to their respective indicators). PANSS POS, PANSS DISORG, BNSS avolition, neurocognition and
incentives are independent predictors. Social cognition, functional capacity, internalized stigma, resilience and service engagement are mediators,
and SLOF is the dependent variable. PANSS – Positive and Negative Syndrome Scale, POS – positive, DISORG – disorganization, BNSS – Brief
Negative Symptom Scale, EE – poor emotional expression, AVOL – avolition, PROC SPEED – processing speed, ATTN – attention, WORK
MEM – working memory, VERB MEM – verbal memory, VIS MEM – visuospatial memory, PROBL SOLV – problem solving, TASIT – The
Awareness of Social Inference Test, MSCEIT – Mayer-Salovey-Caruso Emotional Intelligence Test, PERC. SELF – perception of self, PERC.
FUTURE – perception of the future, SOCIAL COMPET. – social competence, SLOF – Specific Level of Functioning, PERS – skills in self-care,
ACTIV – community activities, ACC – social acceptability, INTER – interpersonal relationships, WORK – working abilities
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understanding of the pathophysiology of avolition represent
a priority of research in schizophrenia, and the implementa-
tion of treatments targeting motivation is likely to be an
important tool to enable people with schizophrenia to
achieve a meaningful life.
At odds with previous literature (8,13,14,53,97,98), no
impact of depression on real-life functioning was observed
in our study. The discrepancy with previous studies might
be due to the use of different instruments for the assessment
of depression (mostly the Beck Depression Inventory, a self-
report measure, in prior investigations) and the low degree
of severity of depression in our sample (mean score54, with
a cutoff of 6/7 for depression in the CDSS).
Extrapyramidal symptoms, family socio-economic status
and social network were not included in the SEM, as they
showed no or weak associations with SLOF and mediating
variables. As to extrapyramidal symptoms, we cannot exclude
that the prevalence of treatment with second-generation
antipsychotics yielded a floor effect, making their impact on
SLOF negligible, while for both social network and socio-
economic status we cannot rule out the possibility of redun-
dancy with other variables, or poor performance of the used
instruments.
Access to family and social incentives had a negative
association with SLOF, i.e., a higher number of incentives
was associated with a poorer real-life functioning. Due to
the cross-sectional study design, this association may be
interpreted either way, i.e., access to incentives may be due
to functional impairment or incentives may have a negative
impact on real-life functioning. In fact, many patients would
not renounce to the disability pension or the support re-
ceived by the family for a job, as the latter is generally re-
garded as less stable and more effortful. Directly relevant to
this point is the finding by Rosenheck et al (99) that disabili-
ty compensation status, which is often linked to the individ-
ual’s health insurance coverage, had the largest negative
impact on vocational outcomes of all the measured predictors.
In conclusion, we found that some illness-related varia-
bles (neurocognition, disorganization, avolition and posi-
tive symptoms) and incentives predict real-life functioning
either directly or through the mediation of resilience, stig-
ma, social cognition, functional capacity and engagement
with mental health services. The final SEM model explained
about 54% of the SLOF variance, a higher percentage com-
pared with those reported in similar studies that used neuro-
cognition, social cognition, social competence and negative
symptoms to predict real-life functioning (7-25%) (7,22,83,87).
The strengths of this study include the large sample size
and the use of state-of-the-art instruments to assess neuro-
cognitive, psychopathological, social cognition, and person-
al resources domains. Some possible limitations include the
restricted variability range of patients’ clinical characteris-
tics and functioning in the real life (most of the patients
showed a mild/moderate degree of symptoms severity and
functional impairment); the use of SLOF as a latent vari-
able, which might have advantages, but might also prevent
the identification of predictors of specific domains, and the
cross-sectional design, which does not allow to test causal
relationships.
Our findings can have important treatment and research
implications. The impact of neurocognition and social cog-
nition on real-life functioning suggests that training address-
ing neurocognitive and social cognition impairment should
be part of integrated treatment packages for schizophrenia.
A greater emphasis on social cognition than on neurocogni-
tion has been suggested, given the greater proximity and
higher direct explanatory power of the former, with respect
to the latter domain (100). However, there is no evidence
that social cognitive training alone counteracts neurocogni-
tive impairment, whose impact on other domains, i.e., func-
tional capacity and service engagement, would probably
persist, in spite of possible improvement in social cognition.
The complexity of the pathway from neurocognition to
real-life functioning through internalized stigma suggests
that, in order to enhance the impact of interventions target-
ing neurocognitive impairment on functioning in the real
life, we also need to promote reduction of internalized stig-
ma related to mental illness and minimize its negative
effects. Data have been provided that anti-stigma interven-
tions are effective at reducing internalized stigma (101-103),
but the impact of such positive outcome on other dimen-
sions of the disorder and on patients’ functioning does need
further investigation.
Our finding that avolition is an independent domain with
respect to both neurocognition and social cognition suggests
that the search for treatments with an impact on this domain
should be a priority of mental health research strategies.
The contribution of resilience to real-life functioning high-
lights the importance of personalization when designing
treatment plans and defining life goals together with our
patients. Prejudicial optimistic or, more frequently, pessimis-
tic attitudes should always be modulated by the awareness
that individuals do vary a lot in terms of personal resources,
and such a variability does not allow undue generalization.
Improved understanding of factors that hinder real-life
functioning is vital for treatments to translate into more pos-
itive outcomes. Findings from the present study provide a
valuable contribution in this direction; in particular, the
observed complex associations among investigated predic-
tors, mediators and real-life functioning strongly suggest
that integrated and personalized programs should be pro-
vided as standard treatment to people with schizophrenia.
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